Retrospective Study
Copyright ©The Author(s) 2023.
World J Gastroenterol. Nov 7, 2023; 29(41): 5641-5656
Published online Nov 7, 2023. doi: 10.3748/wjg.v29.i41.5641
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Kaplan-Meier plot of overall survival. A: Kaplan-Meier plot of overall survival (OS) in all patients; B: Kaplan-Meier plot of OS in group A; C: Kaplan-Meier plot of OS in group B; D: Kaplan-Meier plot of OS in group C. Group A: Chemoradiotherapy plus pembrolizumab; Group B: Neoadjuvant therapy plus pembrolizumab; Group C: Chemotherapy plus pembrolizumab; OS: Overall survival; CI: Confidence interval.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Kaplan-Meier plot of progression-free survival. A: Kaplan-Meier plot of progression-free survival (PFS) in group A; B: Kaplan-Meier plot of disease-free survival in group B; C: Kaplan-Meier plot of PFS in group C. Group A: Chemoradiotherapy plus pembrolizumab; Group B: Neoadjuvant therapy plus pembrolizumab; Group C: Chemotherapy plus pembrolizumab; PFS: Progression-free survival; CI: Confidence interval; DFS: Disease-free survival.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 Kaplan-Meier plot of overall survival in partial response and stable disease. A: Kaplan-Meier plot of overall survival (OS) in partial response (PR) and stable disease (SD) at the midterm evaluation in all patients; B: Kaplan-Meier plot of OS in PR and SD at the midterm evaluation in group A; C: Kaplan-Meier plot of OS in PR and SD at the midterm evaluation in group B; D: Kaplan-Meier plot of OS in PR and SD at the midterm evaluation in group C. PR: Partial response; SD: Stable disease; HR: Hazard ratio; OS: Overall survival; group A: Chemoradiotherapy plus pembrolizumab; group B: Neoadjuvant therapy plus pembrolizumab; group C: Chemotherapy plus pembrolizumab.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 Kaplan-Meier plot of overall survival at baseline. A: Kaplan-Meier plot of overall survival (OS) at baseline (neutrophil-to-lymphocyte ratio < 2.43 vs > 2.43); B: Kaplan-Meier plot of OS at baseline (platelet-to-lymphocyte ratio < 139.7 vs > 139.7); C: Kaplan-Meier plot of OS at baseline [neutrophil-to-(leukocyte-neutrophil) ratio < 1.72 vs > 1.72]. OS: Overall survival; NLR: Neutrophil-to-lymphocyte ratio; PLR: Platelet-to-lymphocyte ratio; dNLR: Neutrophil-to-(leukocyte-neutrophil) ratio; CI: Confidence interval; HR: Hazard ratio.